01 Transition From Passive Storage to Active Organ AssessmentThe kidney preservation market analysis shows that the procedure is moving beyond simply maintaining organs at low temperatures toward technologies that continuously assess organ function and viability during preservation. Hypothermic machine perfusion is increasingly used because it allows physiological parameters to be monitored during transport, while normothermic systems evaluate kidney function before transplantation.
02 Emergence of Physiological Normothermic PerfusionNormothermic systems are being designed to maintain kidneys under conditions closer to normal body physiology rather than relying only on hypothermic preservation. A 2026 study reported that physiological normothermic perfusion maintained kidney viability for 12 hours while improving metabolic stability and reducing indicators of injury. (Source: PubMed)
01 The kidney preservation market forecasts strategic investment activity driven by advances in kidney perfusion, machine perfusion, and organ preservation solutions. In September 2025, The National Kidney Foundation's Innovation Fund invested in BMI OrganBank to support preparations for clinical studies of its room-temperature machine perfusion (RTMP) platform. The technology is designed to preserve kidneys, assess organ function before transplantation, and extend preservation time.
01 Demand for Therapeutic Perfusion to Recondition Donor Kidneys Drive MarketThe need to improve the usability of compromised donor kidneys is creating demand for specialized kidney preservation products such as perfusion systems that can deliver drugs, oxygen, nutrients, or other therapies before transplantation. Ex-vivo normothermic perfusion provides a platform for real-time organ assessment and targeted treatment, expanding its role beyond conventional preservation.
02 Need to Increase Utilization of Marginal Donor Kidneys Boost Market GrowthThe shortage of suitable donor organs is increasing demand for preservation technologies that can assess and recover kidneys previously considered unsuitable for transplantation. Machine perfusion enables transplant centers to evaluate organ function before accepting higher-risk grafts, helping expand the usable donor pool. In a 2026 American Journal of Transplantation study, 94 of 104 previously declined kidneys (90%) were rescued for transplantation after two hours of centralized normothermic machine perfusion.
03 Impact Analysis of Key Drivers in Kidney Preservation MarketDriversMarket ImpactDemand for Therapeutic PerfusionDemand for ex-vivo perfusion systems is supported by transplant centers seeking to assess and potentially restore compromised kidneys before implantation.Need to Increase Utilization of Marginal Donor KidneysThe shortage of transplantable kidneys is increasing demand for kidney preservation devices that can evaluate higher-risk organs.Demand for Longer Organ Transport WindowsLonger and more flexible preservation periods are creating demand for kidney preservation solutions that can maintain viability during extended transportation and improve allocation across geographically dispersed donor and transplant centers.Need to Reduce Delayed Graft FunctionThe clinical need to reduce delayed graft function is supporting adoption of machine perfusion because better preservation can improve early post-transplant kidney performance.Demand for Objective Pre-Transplant Organ AssessmentThe need for reliable viability information is supporting demand for kidney preservation equipment that provides real-time measurements such as renal blood flow, urine output, oxygen consumption, and metabolic markers before a kidney is accepted for transplantation.
01 High Cost of Machine Perfusion Procedures Limit AdoptionHigh equipment, consumable, and operating costs limit adoption, particularly at smaller transplant centers with lower procedure volumes. A 2026 German survey found that 50% of centers identified cost as the biggest barrier, while kidney perfusion generated additional costs of about €6,726 per kidney at one university hospital. (Source: PubMed)
02 Shortage of Specialized Perfusion Personnel Restrict Market GrowthThe operation of advanced kidney preservation systems requires trained personnel to manage perfusion circuits, monitor organ parameters, and respond to technical complications, increasing staffing requirements at transplant centers. This dependence on specialized expertise delays adoption in smaller hospitals and centers that lack dedicated organ perfusion teams.
03 Impact Analysis of Key Restraints in Kidney Preservation MarketRestraintsMarket ImpactHigh Cost of Machine Perfusion ProceduresHigh equipment, disposable, perfusate, and staffing costs can make machine perfusion difficult to justify for transplant centers operating under constrained budgets.Shortage of Specialized Perfusion PersonnelLimited availability of trained perfusion teams restricts the use of complex preservation systems, particularly at kidney-only transplant centers where dedicated machine-perfusion programs are less established.Dependence on Specialized Perfusion ConsumablesRequirements for oxygen carriers, blood products, preservation solutions, and specialized disposable circuits create additional procurement and logistical burdens for normothermic perfusion programs.Risk of Organ Loss from Device FailureTechnical malfunction during perfusion can rapidly compromise a kidney by causing thrombosis or additional ischemic injury, making reliability a significant barrier to wider adoption.Competition From Established Hypothermic PreservationEstablished hypothermic machine perfusion remains widely used for kidney preservation, limiting the need for more complex normothermic systems where cold perfusion already provides acceptable preservation outcomes.
01 Therapeutic Delivery During Ex-Vivo Perfusion Expand Market PotentialTherapeutic perfusion creates revenue opportunities for kidney preservation manufacturers beyond preservation through the sale of drug-loaded perfusates, cell-based therapies, and organ-reconditioning protocols alongside NMP systems. A 2026 systematic review identified 21 therapeutic NMP studies, including 12 kidney studies, covering pharmacological and cellular/subcellular interventions, supporting the emergence of NMP as a treatment platform rather than only a preservation tool.
02 Development of Portable Kidney Perfusion Systems Open New Revenue AvenuesPortable systems open revenue avenues through transport-capable equipment, recurring single-use perfusion sets, monitoring services, and rentals or leasing for organ procurement organizations
August 2026 Organ Recovery Systems and OnAsset Intelligence entered a strategic partnership to integrate OnAsset's SENTRY 600 FlightSafe tracking and sensing device with the LifePort Kidney Transporter.
July 2026 Paragonix Technologies reported two successful kidney transplants involving organs transported from Hawaii to separate transplant centers in New York and Connecticut using its KidneyVault Portable Renal Perfusion System.
March 2026 Paragonix Technologies completed its 1,000th clinical case using the FDA-cleared KidneyVault system in partnership with Donor Network of Arizona.
March 2026 Vivalyx announced the first-in-human use of Vivalyx Omnisol, an investigational organ preservation solution, in a kidney transplantation clinical trial at Erasmus Medical Center in the Netherlands.